ASTM F1925 - 17 - Standard Specification for Semi-Crystalline Poly(lactide) Polymer and Copolymer Resins for Surgical Implants
Our payment provider will performing maintenance on 4th March 2021 between 4AM and 6AM UK time. During this period, you may experience slight interruptions when placing card orders. Please accept our apologies for any inconvenience caused during this essential maintenance.

ASTM F1925 - 17

Standard Specification for Semi-Crystalline Poly(lactide) Polymer and Copolymer Resins for Surgical Implants

Status : Current   Published : December 2017



1.1 This specification covers virgin semi-crystalline poly( l-lactide) or poly( d-lactide) homopolymer resins intended for use in surgical implants. This specification also covers semi-crystalline resins of l-lactide copolymerized with other bioabsorbable monomers including, but not limited to, glycolide, d-lactide, and dl-lactide. The poly( l -lactide) or poly( d-lactide) based homopolymers and copolymers covered by this specification possess lactide segments of sufficient length to allow potential for their crystallization upon annealing.

1.2 Since poly(glycolide) is commonly abbreviated as PGA for poly(glycolic acid) and poly(lactide) is commonly abbreviated as PLA for poly(lactic acid), these polymers are commonly referred to as PGA, PLA, and PLA:PGA resins for the hydrolytic byproducts to which they respectively degrade. PLA is a term that carries no stereoisomeric specificity and therefore encompasses both the amorphous atactic/syndiotactic dl-lactide based polymers and copolymers as well as the isotactic d-PLA and l-PLA moieties, each of which carries potential for crystallization. Inclusion of stereoisomeric specificity within the lactic acid based acronyms results in the following: poly( l-lactide) as P lLA for poly( l-lactic acid), poly( d-lactide) as P dLA for poly( d-lactic acid), and poly( dl-lactide) as P dlLA for poly( dl-lactic acid).

1.3 This specification is applicable to lactide-based polymers or copolymers that possess isotactic polymeric segments sufficient in size to carry potential for lactide-based crystallization. Such polymers typically possess nominal mole fractions that equal or exceed 50 % l-lactide. This specification is particularly applicable to isotactic-lactide based block copolymers or to polymers or copolymers synthesized from combinations of d-lactide and l-lactide that differ by more than 1.5 total mole percent (1.5 % of total moles). This specification is not applicable to lactide-co-glycolide copolymers with glycolide mole fractions greater than or equal to 70 % (65.3 % in mass fraction), which are covered by Specification F2313. This specification is not applicable to amorphous polymers or copolymers synthesized from combinations of d-lactide and l-lactide that differ by less than 1.5 total mole percent (1.5 % of total moles) as covered by Specification F2579.

1.4 This specification covers virgin semi-crystalline poly(lactide)-based resins able to be fully solvated at 30°C by either methylene chloride (dichloromethane) or chloroform (trichloromethane). This specification is not applicable to lactide:glycolide copolymers that possess glycolide segments sufficient in size to deliver potential for glycolide-based crystallization, thereby requiring fluorinated solvents for complete dissolution under room temperature conditions (see Specification F2313).

1.5 Within this specification, semi-crystallinity within the resin is defined by the presence of a DSC (differential scanning calorimetry) crystalline endotherm after annealing above the glass transition temperature. While other copolymeric segments may also crystallize upon annealing (for example, glycolide), specific characterization of crystalline structures other than those formed by lactide are outside the scope of this specification.

1.6 This specification addresses material characteristics of the virgin semi-crystalline poly(lactide) based resins intended for use in surgical implants and does not apply to packaged and sterilized finished implants fabricated from these materials.

1.7 As with any material, some characteristics may be altered by processing techniques (such as molding, extrusion, machining, assembly, sterilization, and so forth) required for the production of a specific part or device. Therefore, properties of fabricated forms of this resin should be evaluated independently using appropriate test methods to assure safety and efficacy.

1.8 Biocompatibility testing is not a requirement since this specification is not intended to cover fabricated devices.

1.9 The values stated in SI units are to be regarded as standard. No other units of measurement are included in this standard.

1.10  This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety, health, and environmental practices and determine the applicability of regulatory limitations prior to use.

1.11  This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.

Standard NumberASTM F1925 - 17
TitleStandard Specification for Semi-Crystalline Poly(lactide) Polymer and Copolymer Resins for Surgical Implants
Publication Date15 December 2017
Normative References(Required to achieve compliance to this standard)No other standards are normatively referenced
Informative References(Provided for Information)No other standards are informatively referenced
Descriptors PGA:PLA, PLA, PLA:PGA, PLGA, PLA, polyglycolic:lactic acid, poly(glycolide:lactide), poly(lactic acid), polylactic:glycolic acid, polylactide, poly(lactide), poly(lactide:glycolide), poly(lactic acid)
File Size172 KB

 Your basket
Your basket is empty

Multi-user access to over 3,500 medical device standards, regulations, expert commentaries and other documents

Worldwide Standards
We can source any standard from anywhere in the world

Tracked Changes

Understand the changes made to a standard with our new Tracked Changes version

Develop a PAS

Develop a fast-track standardization document in 9-12 months